Insider trade

Officer received an award of 22K ABT derivative securities

Traded Feb 24, 2026 · Filed Feb 26, 2026

Abbott LaboratoriesABT

22K
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 24, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 26, 2026

OfficerGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001644207-26-000002
Filed / recorded

Feb 26, 2026, 11:35 PM UTC

Added to OQRO

Oct 2, 2026, 12:26 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

ABBOTT LABORATORIES

Issuer CIK

1800

Ticker

ABT

Reporting person

John A. Jr. Mccoy

Relationship

Officer

Officer title

VICE PRESIDENT AND CONTROLLER

Security

Option (right to buy)

Table

Derivative (Table II)

Transaction date

Feb 24, 2026

Transaction code

A

Shares / units

22,151

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

22,151

Ownership form

Direct

Amendment

No

Footnotes from the filing

Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,383 on February 24, 2027, 7,384 on February 24, 2028, and 7,384 on February 24, 2029.